Literature DB >> 26568562

The relationship between the rate of brain volume loss during first 24 months and disability progression over 24 and 48 months in relapsing MS.

Douglas R Jeffery1, Elisabetta Verdun Di Cantogno2, Shannon Ritter3, Daniela Piani Meier2, Ernst-Wilhelm Radue4, William Camu5.   

Abstract

Clinical evidence in patients with relapsing-remitting multiple sclerosis suggests an association between MRI outcome measures and disability progression (DP). Post hoc analysis to investigate the association and potential predictive value of brain volume loss (BVL) with long-term DP in FREEDOMS. Patients were categorized into quartiles by SIENA-calculated percent brain volume change from baseline to month (M) 24. Patient characteristics at baseline were determined for each quartile, as were the proportions of patients at M24 and M48 reaching Expanded Disability Status Scale (EDSS) scores of ≥4.0 or ≥6.0 or DP confirmed at 3 months (CDP3) or 6 months (CDP6), and change in EDSS and Multiple Sclerosis Functional Composite. MS disease activity and severity as well as brain volume at baseline were predictive of subsequent BVL over 24 months. The quartiles of patients with greater BVL at 24 months were at highest risk (odds ratio, p value) for reaching EDSS ≥4 (2.8, p = 0.001) or ≥6 (5.73, p = 0.0005) and experienced more DP at M24 (CDP3 2.13, p = 0.002; CDP6 2.17, p = 0.003) and M48 (CDP3 1.98, p = 0.006; CDP6 1.87, p = 0.018) compared to the quartile of patients with the least amount of BVL. These findings confirm the clinical relevance of early brain volume changes for long-term DP.

Entities:  

Keywords:  Brain volume loss; Disability progression; Magnetic resonance imaging; Relapsing-remitting multiple sclerosis

Mesh:

Substances:

Year:  2015        PMID: 26568562     DOI: 10.1007/s00415-015-7959-1

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis.

Authors:  Maria Pia Sormani; Douglas L Arnold; Nicola De Stefano
Journal:  Ann Neurol       Date:  2014-01-02       Impact factor: 10.422

Review 2.  Multiple sclerosis - candidate mechanisms underlying CNS atrophy.

Authors:  Volker Siffrin; Johannes Vogt; Helena Radbruch; Robert Nitsch; Frauke Zipp
Journal:  Trends Neurosci       Date:  2010-02-12       Impact factor: 13.837

3.  A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis.

Authors:  R Zivadinov; J Sepcic; D Nasuelli; R De Masi; L M Bragadin; M A Tommasi; S Zambito-Marsala; R Moretti; A Bratina; M Ukmar; R S Pozzi-Mucelli; A Grop; G Cazzato; M Zorzon
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-06       Impact factor: 10.154

4.  Impact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosis.

Authors:  Ernst-Wilhelm Radue; Paul O'Connor; Chris H Polman; Reinhard Hohlfeld; Peter Calabresi; Krystof Selmaj; Nicole Mueller-Lenke; Catherine Agoropoulou; Frederick Holdbrook; Ana de Vera; Lixin Zhang-Auberson; Gordon Francis; Pascale Burtin; Ludwig Kappos
Journal:  Arch Neurol       Date:  2012-10

5.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

6.  Brain atrophy and lesion load predict long term disability in multiple sclerosis.

Authors:  Veronica Popescu; Federica Agosta; Hanneke E Hulst; Ingrid C Sluimer; Dirk L Knol; Maria Pia Sormani; Christian Enzinger; Stefan Ropele; Julio Alonso; Jaume Sastre-Garriga; Alex Rovira; Xavier Montalban; Benedetta Bodini; Olga Ciccarelli; Zhaleh Khaleeli; Declan T Chard; Lucy Matthews; Jaqueline Palace; Antonio Giorgio; Nicola De Stefano; Philipp Eisele; Achim Gass; Chris H Polman; Bernard M J Uitdehaag; Maria Jose Messina; Giancarlo Comi; Massimo Filippi; Frederik Barkhof; Hugo Vrenken
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-03-23       Impact factor: 10.154

7.  Predictors of long-term outcome in multiple sclerosis patients treated with interferon β.

Authors:  Robert A Bermel; Xiaojun You; Pamela Foulds; Robert Hyde; Jack H Simon; Elizabeth Fisher; Richard A Rudick
Journal:  Ann Neurol       Date:  2013-01       Impact factor: 10.422

8.  Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis.

Authors:  Serkan Ozakbas; Inanc Cagiran; Burcu Ormeci; Egemen Idiman
Journal:  J Neurol Sci       Date:  2004-03-15       Impact factor: 3.181

Review 9.  Cognitive reserve in multiple sclerosis.

Authors:  James F Sumowski; Victoria M Leavitt
Journal:  Mult Scler       Date:  2013-08       Impact factor: 6.312

10.  Cognitive reserve and symptom experience in multiple sclerosis: a buffer to disability progression over time?

Authors:  Carolyn E Schwartz; Brian R Quaranto; Brian C Healy; Ralph H Benedict; Timothy L Vollmer
Journal:  Arch Phys Med Rehabil       Date:  2013-05-28       Impact factor: 3.966

View more
  5 in total

1.  Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS study.

Authors:  Douglas L Arnold; Brenda Banwell; Amit Bar-Or; Angelo Ghezzi; Benjamin M Greenberg; Emmanuelle Waubant; Gavin Giovannoni; Jerry S Wolinsky; Jutta Gärtner; Kevin Rostásy; Lauren Krupp; Marc Tardieu; Wolfgang Brück; Tracy E Stites; Gregory L Pearce; Dieter A Häring; Martin Merschhemke; Tanuja Chitnis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-04       Impact factor: 10.154

2.  MRI phenotypes in MS: Longitudinal changes and miRNA signatures.

Authors:  Christopher C Hemond; Brian C Healy; Shahamat Tauhid; Maria A Mazzola; Francisco J Quintana; Roopali Gandhi; Howard L Weiner; Rohit Bakshi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-02-14

3.  Different Doses of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Xin Wu; Tao Xue; Zilan Wang; Zhouqing Chen; Xuwei Zhang; Wei Zhang; Zhong Wang
Journal:  Front Pharmacol       Date:  2021-05-17       Impact factor: 5.810

Review 4.  MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice.

Authors:  Jaume Sastre-Garriga; Deborah Pareto; Marco Battaglini; Maria A Rocca; Olga Ciccarelli; Christian Enzinger; Jens Wuerfel; Maria P Sormani; Frederik Barkhof; Tarek A Yousry; Nicola De Stefano; Mar Tintoré; Massimo Filippi; Claudio Gasperini; Ludwig Kappos; Jordi Río; Jette Frederiksen; Jackie Palace; Hugo Vrenken; Xavier Montalban; Àlex Rovira
Journal:  Nat Rev Neurol       Date:  2020-02-24       Impact factor: 42.937

5.  Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis.

Authors:  Bruce Ac Cree; Jeffrey A Cohen; Anthony T Reder; Davorka Tomic; Diego Silva; Daniela Piani Meier; Annik K Laflamme; Shannon Ritter; David Leppert; Ludwig Kappos
Journal:  Mult Scler       Date:  2021-03-26       Impact factor: 6.312

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.